AstraZeneca PLC (AZN)vsXWELL Inc. (XWEL)
AZN
AstraZeneca PLC
$169.64
-0.99%
HEALTHCARE · Cap: $263.09B
XWEL
XWELL Inc.
$0.98
-10.09%
HEALTHCARE · Cap: $8.87M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 212792% more annual revenue ($61.37B vs $28.82M). AZN leads profitability with a 17.0% profit margin vs -81.4%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
XWEL
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$169.64
$27.29 discount
Margin of Safety
+59.0%
Fair Value
$0.96
Current Price
$0.98
$0.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -333.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : XWEL
XWEL has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : XWEL
The primary concerns for XWEL are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 21.37 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 1.03 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 21/100), backed by strong 17.0% margins. XWEL offers better value entry with a 59.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?